Supplementary Figure 1: Wild-type and homozygous fl1A mice have similar behavioral and neurogenic responses to fluoxetine treatment.

a) Floxed 1A mice were generated and compared to wild-type littermates. White triangles indicates loxP sites. Htr1A p.: 5HT1AR promoter; Htr1A e1: 5HT1AR exon; pA: polyadenylation signal. Timeline is for panels b-h. Wild-type (WT) or homozygous fl1A (fl1A (Control)) mice were treated with daily fluoxetine (18 mg/kg) or vehicle administration that began when the mice were 8 weeks old. Behavior commenced three weeks after the start of fluoxetine treatment, and mice were administered BrdU (150 mg/kg) six weeks after the start of fluoxetine treatment and 2 hours before sacrifice. For behavior, n = 16-17 per group. For neurogenesis, n=8 per group randomly chosen from the behavioral cohort. b) NSF results. *** indicates p = .0001 for WT Vehicle vs Fluoxetine and p<.0001 for fl1A Vehicle vs Fluoxetine. Latencies were analyzed using Kaplan-Meier Survival Analysis with Bonferroni correction and Mantel-Cox p-values. c) Percentage weight loss and home cage consumption controls for the NSF experiment. The percentage of weight lost during the deprivation period and the amount of food consumed over 5 min when the mice were placed back into their home cage immediately after NSF exposure were calculated. No significant differences were seen among genotype and treatment groups (Two-Way ANOVA). d) EPM results. Bar graphs indicating open arm entries (left) and open arm duration (right) are shown. For both open arm entries (left) and open arm duration (right) there were only significant main effects of treatment (Two-Way ANOVA assessing genotype/treatment, *** indicates p<.0001 treatment effect for both open arm entries and open arm duration). e) FST results. For immobility duration there were only significant main effects of treatment (Two-Way ANOVA assessing genotype/treatment, *** indicates p<.0001 treatment effect). f) Proliferation results. For the number of BrdU-positive cells, there were only significant main effects of treatment (Two-Way ANOVA assessing genotype/treatment, *** indicates p<.0001 treatment effect). g) The number of abGCs. For the number of Dcx-positive cells, there were only significant main effects of treatment (Two-Way ANOVA assessing genotype/treatment, *** indicates p<.0001 treatment effect). h) The number of abGCs with tertiary dendrites. For the number of Dcx-positive cells with tertiary dendrites, there were only significant main effects of treatment (Two-Way ANOVA assessing genotype/treatment, *** indicates p<.0001 treatment effect). Bars and error bars throughout the figure represent mean ± SEM.